Sugi Predict

Sugi Predict / Compounds / SCHEMBL4381893

SCHEMBL4381893

SCHEMBL4381893

[O]C[C@H](O)CN1CCCC1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.68
▸ KMT2A Q03164 3/20 0.68
▸ ATM Q13315 2/20 0.62
▸ MAPT P10636 1/20 0.62
▸ HSD17B10 Q99714 2/20 0.55
▸ USP2 O75604 1/20 0.44
▸ CYP2D6 P10635 2/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ ANPEP P15144 1/20 0.42
▸ ERAP2 Q6P179 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GLA P06280 1/20 0.41
▸ ACE2 Q9BYF1 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382056 1.00 MEN1 (0.68) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL10476 1.00 MEN1 (0.68) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL5218126 0.98 MEN1 (0.73) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL4378009 0.98 MEN1 (0.73) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL4376156 0.98 MEN1 (0.73) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL7572149 0.98 MEN1 (0.73) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL2434746 0.98 MEN1 (0.73) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL7571912 0.95 — —
SCHEMBL10895166 0.84 MEN1 (0.94) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL7575576 0.82 SMN1; SMN2 (0.47) MEN1KMT2AATMMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 — — US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 — — US disclosed
EP-1453492-B1 USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES ASTRAZENECA AB (SE) 2007-01-24 — — EP disclosed
US-7157467-B2 Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis ASTRAZENECA AB (SE) 2007-01-02 — — US disclosed
US-7115615-B2 Quinazoline derivatives ASTRAZENECA (SE) 2006-10-03 — — US disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 — — US disclosed
US-20060148819-A1 Chemical compounds HENNEQUIN LAURENT F A 2006-07-06 — — US disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 — — EP disclosed
US-6887874-B2 Cinnoline compounds ASTRAZENECA AB (SE) 2005-05-03 — — US disclosed
US-6849625-B2 Quinazoline derivatives with anti-tumour activity ASTRAZENECA AB (SE) 2005-02-01 — — US disclosed
US-20050014773-A1 Therapeutic use ASTRAZENACA AB (SE) 2005-01-20 — — US disclosed
US-20030212055-A1 Cinnoline compounds ASTRAZENECA AB (SE) 2003-11-13 — — US disclosed
US-20030207878-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-11-06 — — US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US disclosed
WO-2002016348-A1 ANTIANGIOGENIC BICYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 MEN1 693/4885KMT2A 2959/4885ATM 3979/4885
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR MEN1 2314/4885KMT2A 3862/4885ATM 3304/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 MEN1 1032/4885KMT2A 3871/4885ATM 4765/4885
US-20060148819-A1 Chemical compounds VEGFA, NOS3, FLT4 MEN1 603/4885KMT2A 4224/4885ATM 2975/4885
US-20050014773-A1 Therapeutic use CD4, HLA-DRB1, CD74 MEN1 372/4885KMT2A 2659/4885ATM 3982/4885
US-20030207878-A1 Chemical compounds CYP3A7, HTR3C, CNR1 MEN1 188/4885KMT2A 2471/4885ATM 4555/4885
US-20030212055-A1 Cinnoline compounds VEGFA, PGF, CCR7 MEN1 182/4885KMT2A 3184/4885ATM 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.